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Connexin43 (Cx43) function is inﬂuenced by kinases that phosphorylate speciﬁc serine sites located near its C-terminus.
Stroke is a powerful inducer of kinase activity, but its effect on Cx43 is unknown. We investigated the impact of wild-type (WT)
and knock-in Cx43 with serine to alanine mutations at the protein kinase C (PKC) site Cx43S368A, the casein kinase 1 (CK1)
sites Cx43S325A/328Y/330A, and the mitogen-activated protein kinase (MAPK) sites Cx43S255/262/279/282A (MK4) on a permanent
middle cerebral artery occlusion (pMCAO) stroke model. We demonstrate that MK4 transgenic animals exhibit a signiﬁcant
decrease in infarct volume that was associated with improvement in behavioral performance. An increase in astrocyte
reactivity with a concomitant decrease in microglial reactivity was observed in MK4 mice. In contrast to WT, MK4 astrocytes
displayed reduced Cx43 hemichannel activity. Pharmacological blockade of Cx43 hemichannels with TAT-Gap19 also
signiﬁcantly decreased infarct volume in WT animals. This study provides novel molecular insights and charts new avenues
for therapeutic intervention associated with Cx43 function.
Introduction
Ischemic stroke is a complex event characterized by cell death
resulting from a transient or permanent arterial occlusion
(Sacco et al., 2013). Astrocytic connexin43 (Cx43) gap junction
(GJ) channels have been reported to impact neuronal survival in
ischemic conditions (Siushansian et al., 2001; Nakase et al.,
2004; Kozoriz et al., 2010), but Cx43 knockout versus pharma-
cological inhibition of Cx43 has often produced divergent out-
comes (reviewed in Schulz et al., 2015). Astrocyte GJs are
composed primarily of the channel protein Cx43 and, to a lesser
extent, Cx30 and Cx26 (Naus et al., 1991; Giaume, 1996). Cx43
protein hexamers form transmembrane channels, termed con-
nexons, which then couple with apposing connexons on neigh-
boring cells and coalesce into dense GJ plaques. Astrocytic cell
networks coupled by Cx43 GJs allow for the intercellular ex-
change of metabolites and second messengers (Goodenough and
Paul, 2009). However, Cx43 channels also form hemichannels
that connect the cell cytoplasm to the extracellular milieu
(Orellana et al., 2009; Giaume et al., 2013). Hemichannels are
mostly active under pathological conditions and facilitate the
entry of Na+ and Ca2+ into the cell and the escape of K+, ATP, and
other molecules, potentially contributing to autocrine/paracrine
signaling but also leading to the loss of essential metabolites
(Chever et al., 2014; D’hondt et al., 2014; Schulz et al., 2015).
The C-terminus (CT) of Cx43 plays a key role in channel
function, harboring putative phosphorylation sites speciﬁc to
different kinases that directly regulate Cx43 activity (Solan and
Lampe, 2009; Chen et al., 2013; Pogoda et al., 2016). Interest-
ingly, mice expressing a truncated mutant form of Cx43 lacking
the CT (Cx43ΔCT; truncation at amino acid 258), exhibited in-
creased stroke damage and inﬂammation (Kozoriz et al., 2010).
The deletion was shown to have a dominant negative effect in
ischemic damage in mice expressing both WT and Cx43ΔCT
alleles (Kozoriz et al., 2010), underscoring the critical role Cx43
CT plays in stroke.
Ischemia activates cellular kinases, several of which
have been linked with Cx43. We tested whether Cx43
phosphorylation–null mutants show signiﬁcant differences to
permanent middle cerebral artery occlusion (pMCAO). WT and
knock-in mice containing null phosphorylation mutations at
Cx43 CT sites known to be substrates for casein kinase 1 (CK1),
protein kinase C (PKC), or MAPK were subjected to pMCAO. 4 d
after pMCAO, MAPK Cx43S255/262/279/282A (MK4) mutant mice
showed several signiﬁcant differences compared with WT
counterparts, including a reduction in infarct volume, a de-
crease in apoptosis and inﬂammation, and an increase in as-
trocyte reactivity. These quantitative differences also correlated
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with positive behavioral outcome in MK4 ischemic mice. In
contrast, no signiﬁcant differences in infarct volume were ob-
served in the CK1 Cx43S325A/328Y/330A- and PKC Cx43S368A-null
phosphorylation mutant animals. In addition, we demonstrate
that the protective effect of theMK4mutation during pMCAO is
due to a reduction in Cx43 hemichannel activity. The mecha-
nism was validated with the administration of the Cx43 hemi-
channel blocker TAT-Gap19 (Wang et al., 2013; Abudara et al.,
2014) in ischemic WT mice.
Results
MK4 mice are protected following ischemic stroke
Among the known kinases that interact with Cx43 CT, CK1, PKC,
and MAPK are active in ischemic conditions (Jiang et al., 2002;
Freitas-Andrade et al., 2008; Kaneko et al., 2014; Demyanenko
et al., 2015). To test whether disrupting CK1, PKC, or MAPK
phosphorylation sites of the Cx43 C-terminal tail (Fig. 1) im-
pacts stroke outcome, male and female WT and Cx43
phosphorylation–null mutants for CK1, PKC, and MAPK (MK4)
mice were subjected to pMCAO. 4 d after pMCAO, CK1 and PKC
Cx43 phosphorylation–null mutant mice did not show signiﬁ-
cant changes in infarct volume with respect to WT controls
(Fig. 2, A and B). However, MK4 mice exhibited a signiﬁcant
(P = 0.0181) 58.3% reduction in infarct volume compared with
their WT counterparts (Fig. 2, A and B).
In light of the compelling phenotype observed in MK4 is-
chemic mice, a larger cohort of WT and MK4 male and female
animals were subjected to pMCAO. Consistent with our initial
study, MK4 mice exhibited a signiﬁcant (P = 0.0053) 40.2%
reduction in infarct volume compared with WT counterparts
(Fig. 2 C). In addition, we found no signiﬁcant differences in the
cortical area supplied by the middle cerebral artery (MCA) be-
tween WT and MK4 mice (data not shown).
Apoptosis triggered by an ischemic event may occur over
several days and contribute to delayed neuronal death and loss
of viable peri-infarct tissue (Nakase et al., 2004). To investigate
whether the difference in infarct volume found in WT and MK4
ischemic mice is correlated with differences in the level of ap-
optosis, WT and MK4 brain sections from ischemic mice were
subjected to TUNEL immunostaining. A signiﬁcant (P = 0.0322)
reduction (57.7%) in the number of apoptotic TUNEL+ cells
Figure 1. Schematic indicating MAPK, CK1 and PKC phosphorylation sites on Cx43 CT domain. Box shows peptides used in this study (sequences in-
dicated on Cx43 protein in corresponding color). Pep-1 and CT9 fused to TAT were used for in vitro work (Fig. 6); TAT-Gap19 was used for in vivo experiments
(Fig. 8). NT, N-terminal end; IL, intracellular loop; EL, extracellular loop.
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within the infarct region of MK4 sections was seen 4 d after
pMCAO (Fig. 2, D and E). This was consistent with the positive
thionin tissue staining within the infarct area of MK4 brain
sections, indicating viable brain tissue (Fig. 2 A).
MK4 mice exhibit increased astrocyte and decreased microglia
reactivity after pMCAO
Both reactive astrocytes and reactive microglia participate in
stroke-induced gliosis (Burda and Sofroniew, 2014), which
reaches a maximum at 3–5 d after stroke (Feuerstein et al., 1997;
Nakase et al., 2004). To investigate whether MK4 mice are af-
fected by pMCAO-induced gliosis, the total number and size of
cells immunoreactive for glial ﬁbrillary actin protein (GFAP; an
astrocyte marker) and ionized calcium-binding adaptor mole-
cule 1 (Iba1; a microglial marker) were evaluated in bothWT and
MK4 brain sections 4 d after pMCAO (see Fig. S1 for analysis
detail).
In both WT and MK4 brain sections, an increase in the
number of GFAP+ cells per ﬁeld of view was observed in the
peri-infarct region (Fig. 3 A). However, brain sections from is-
chemic MK4 mice showed a signiﬁcantly (P = 0.0061) larger
(65.9%) increase in GFAP+ cell numbers per ﬁeld of view within
the peri-infarct region compared withWTmice (Fig. 3, A and B).
In addition, MK4 GFAP+ cells were signiﬁcantly (P = 0.0109)
Figure 2. Disrupting the MAPK phosphorylation sites of Cx43 CT decreases infarct volume and TUNEL staining 4 d after pMCAO. (A) Photomicro-
graphs of thionin-stained sections fromWT and Cx43-null phosphorylation mutants CK1, PKC, and MAPK (MK4) mice 4 d after pMCAO. Arrows point to infarct
region. Scale bar = 2 mm. (B) Quantiﬁcation of infarct volume from WT and Cx43-null phosphorylation mutants CK1, PKC, and MAPK (MK4) 4 d after pMCAO
(one-way ANOVA followed by Bonferroni post hoc test; *, P = 0.0181; WT: n = 5 mice; CK1: n = 4; PKC: n = 4; MK4: n = 4). (C) Quantiﬁcation of infarct volume
fromWT and MK4 mice 4 d after pMCAO (unpaired Student’s t test; **, P = 0.0053; WT: n = 10 mice; MK4: n = 11 mice). (D) Coimmunoﬂuorescence staining of
cerebral cortex fromWT (left) and MK4 (right) mice 4 d after pMCAO using GFAP (red) with a TUNEL apoptosis marker (green). The white outline is the infarct
area. Scale bar = 500 µm. Tile Scan tool and auto-stitching algorithm in the Leica LAS AF program was used to create high-resolution image montages. (E)
Quantiﬁcation of average number of TUNEL+ cells in brain sections per infarct area in mm2 fromWT and MK4mice 4 d after pMCAO (unpaired Student’s t test;
*, P = 0.0201; WT: four sections, n = 4 mice; MK4: four sections, n = 4 mice). Error bars represent mean ± SEM.
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larger (9.8%) than their WT counterparts (Fig. 3 A, 19 and 29; and
Fig. 3 C). GFAP-labeled sections from MK4 mice recapitulated
the thionin-staining pattern observed in Figs. 2 A and S2.
Microglia are deﬁned partly by their morphological changes,
from nonreactive small cell bodies with several thin processes to
reactive microglia exhibiting a more amoeboid shape with
highly branched short processes and increased Iba1 immuno-
reactivity (Ito et al., 2001). Iba1 immunoﬂuorescent staining of
WT and MK4 brain sections showed an increase in Iba1+ cells in
the peri-infarct region in both genotypes (Fig. 3 D). However,
MK4 sections exhibited a signiﬁcant (P = 0.0448) reduction
(37.4%) in Iba1+ cell numbers per ﬁeld of view compared with
WT counterparts (Fig. 3 E). No size differences in Iba1+ cells
were observed between WT and MK4 brain sections (data not
shown).
Cx43 protein expression and phosphorylation in WT and
MK4 mice
We compared Cx43 spatial distribution and protein levels be-
tween WT and MK4 brain sections, 4 d after pMCAO. Immu-
noﬂuorescent staining of Cx43 showed similar punctate labeling
in bothWT andMK4 brain sections (Fig. 4 A). In both genotypes,
Figure 3. Increase in GFAP+ reactive astrocytes and a decrease in
Iba1+ reactive microglia 4 d after pMCAO in MK4 mice. (A) Immu-
noﬂuorescent GFAP (red) staining of WT (A1 and A19) and MK4 (A2 and
A29) cerebral cortex from mice 4 d after pMCAO. White outlines rep-
resent the border of the infarct region. Boxes A1 and A2 (magniﬁed in
A19 and A29) show a larger size of individual GFAP+ cells in A29 com-
pared with A19. (B) Quantiﬁcation of the average number of GFAP+ cells
per unit area (960 × 600 µm) shows a signiﬁcantly higher number of
GFAP+ cells in MK4 peri-infarct brain tissue (unpaired Student’s t test;
**, P = 0.0013; WT: four sections, n = 5 mice; MK4: four sections, n = 5
mice). (C) Quantiﬁcation of GFAP+ cells reveals a signiﬁcant increase in
their average size in MK4 peri-infarct brain tissue (unpaired Student’s
t test; *, P = 0.0356; WT: four sections per mouse, n = 5 mice; MK4: four
sections per mouse, n = 5 mice). (D) Immunoﬂuorescent staining of WT
(left) and MK4 (right) cortical sections 4 d after pMCAO using the mi-
croglial marker Iba1 (green). The white outline is the border of the in-
farct region. (E) Quantiﬁcation of Iba1+ cell numbers per unit area (960
× 600 µm) shows reduction in number of Iba1+ cells in MK4 brain
sections (unpaired Student’s t test; *, P = 0.0211; WT: four sections per
mouse, n = 4 mice; MK4: four sections per mouse, n = 4 mice). Scale
bars = 100 µm. Error bars represent mean ± SEM.
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Figure 4. Cx43 expression is similar in bothWT andMK4 ischemicmice, and Cx43 phosphorylation at CT Ser sites 279 and 282 correlates withMAPK
activity under ischemia. (A) Cx43 (green) and GFAP (red) labeling in brain sections from WT (left) and MK4 (right) mice 4 d after pMCAO. Increased Cx43
staining was observed adjacent to infarct in both WT and MK4 brain sections. Arrows indicate areas within peri-infarct that did not stain for Cx43 and are
devoid of GFAP signal. Infarct is indicated by the white outline. Scale bar = 100 µm. (B) Immunoblot of phospho-p44/42MAPK (upper blot) and γ-tubulin (lower
blot) from ipsilateral and contralateral cortical brain tissue from WT and MK4 mice 2 h after pMCAO. Right graph shows mean relative band densities for
phospho-p44/42 MAPK protein as a function of side of cortex and genotype. Two-way ANOVA followed by Tukey’s multiple comparisons test, main effect of
genotype, P = 0.5957; main effect of treatment (ipsilateral versus contralateral cortex), ****, P < 0.0001; interaction P = 0.9724; WT ipsilateral versus WT
contralateral: **, P = 0.0082; MK4 ipsilateral versus MK4 contralateral: **, P = 0.0075; WT: n = 4 mice; MK4: n = 4 mice. (C) Immunoblot of Cx43 (upper blot)
and γ-tubulin (lower blot) from ischemic ipsilateral and nonischemic contralateral cortical brain tissue from WT and MK4 mice 2 h after pMCAO. Right graph
shows mean relative band densities for Cx43 as a function of side of cortex and genotype (two-way ANOVA followed by Tukey’s multiple comparisons test; no
signiﬁcant differences were measured between groups; WT: n = 4mice; MK4: n = 4mice). (D) Immunoblot of phospho-p44/42MAPK (upper blot) and γ-tubulin
(lower blot) in WT and MK4 astrocytes subjected to either media plus normoxia (95% O2/5% CO2), 3-h ischemic buffer plus normoxia (95% O2/5% CO2), or 3-h
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Cx43 immunoreactivity was highest adjacent to the infarct, and
signal intensity decreased in proportion to the distance from the
infarct (Fig. 4 A). Within the peri-infarct we observed, in both
genotypes, areas where Cx43 immunostaining was not detected;
these areas devoid of Cx43 also showed relatively reduced or
absent GFAP signal, as indicated by white arrows (Fig. 4 A). This
may represent “mini-infarct cores” surrounded by “mini-
penumbras” as previously reported (del Zoppo et al., 2011).
There is evidence in the literature that Cx43 is expressed in
microglial cells (Eugenı´n et al., 2001). However, in our ischemic
model, we did not detect Cx43 expression inmicroglia in vitro or
in vivo (data not shown).
We tested whether MAPK activity is up-regulated under is-
chemic conditions in WT and MK4 mice 2 h after pMCAO.
Consistent with previous ﬁndings (Wu et al., 2000), MAPK
phosphorylation levels were signiﬁcantly higher (∼1.3-fold) in
the ipsilateral cortex of both WT (P = 0.0082) and MK4 (P =
0.0075) animals compared with the corresponding contralateral
cortex (Fig. 4 B). In both WT and MK4 mice, Cx43 protein levels
were similar in the ipsilateral and contralateral cortical brain
tissue 2 h after pMCAO (Fig. 4 C). However, while the contra-
lateral tissue showed Cx43 bands corresponding to the phos-
phorylated P1 and P2 isoforms, the ipsilateral side showed Cx43
bands corresponding to the P0 isoform as well as the P1 and P2
isoforms in both genotypes (Fig. 4 C).
To delineate the interaction between MAPK elevated phos-
phorylation levels and Cx43 phosphorylation, WT and MK4 as-
trocytes were incubated in ischemic, high-glucose buffer (a
solution that mimics the interstitial ionic concentrations of is-
chemic brain; Bondarenko and Chesler, 2001; Orellana et al.,
2010) compared with WT and MK4 astrocytes in normal me-
dia (all at normoxia). The interaction was investigated within a
3-h timescale, which is approximately equal to the half-life of
Cx43 (Laird, 1996; Safﬁtz et al., 2000). A signiﬁcant (WT: P =
0.0038; MK4: P = 0.0019) increase (∼2.5-fold) in MAPK phos-
phorylation levels was measured in both genotypes after 3 h in
ischemic buffer in high (27 mM) glucose plus normoxia (95% O2/
5% CO2; Fig. 4 D). However, both WT and MK4 astrocytes ex-
posed for 3 h to ischemic buffer in high (27 mM) glucose plus
hypoxia (<1% O2) showed a nonsigniﬁcant (WT: P = 0.20; MK4:
P = 0.085) trend toward higher MAPK phosphorylation com-
pared with media controls (Fig. 4 D). In WT astrocytes, phos-
phorylation of Cx43 sites Ser-279 and Ser-282 correlated with
MAPK activity (Fig. 4, D and E). WT astrocytes exposed for 3 h to
ischemic buffer in high (27 mM) glucose plus normoxia (95% O2/
5% CO2) exhibited a signiﬁcant (P < 0.0001) increase (∼4.2-fold)
in phosphorylation at sites Ser-279 and Ser-282 of Cx43 com-
pared with WT astrocytes in control media conditions (Fig. 4 E).
Consistent with MAPK phosphorylation levels, WT astrocytes
exposed for 3 h to ischemic buffer in high (27 mM) glucose plus
hypoxia (<1% O2) showed a nonsigniﬁcant trend toward higher
phosphorylation levels at Cx43 sites Ser-279 and Ser-282 com-
pared with media controls (Fig. 4 E). Phosphorylation of Ser-279
and Ser-282 of Cx43 was not detected in MK4 astrocytes in ei-
ther condition (Fig. 4 E).
Cx43 GJ coupling is similar between ischemic WT and
MK4 mice
Given that Cx43 GJ channel activity is regulated by MAPK acti-
vation (Retamal et al., 2007; Orellana et al., 2009, 2012; Kozoriz
et al., 2013), Cx43 GJ coupling was evaluated in situ and in vitro
inWT andMK4 astrocytes. WT andMK4mice were subjected to
pMCAO, and after 2 h of ischemia, mice were euthanized, brains
were quickly removed and sliced, and tissue was scraped with a
needle in a solution containing a GJ permeable dye, Lucifer
Yellow (LY) and a GJ-impermeable dye, dextran rhodamine, as
previously described (Desarme´nien et al., 2013). LY diffusion
was signiﬁcantly up-regulated (∼2.6-fold) in the ipsilateral (is-
chemic) compared with the contralateral (nonischemic) cortex
in both WT and MK4 mice (Fig. 5, A and B). LY diffusion in the
contralateral (nonischemic) cortex was similar in both WT and
MK4 brain slices (Fig. 5, A and B). 100 µM carbenoxelone (CBX),
a known connexin blocker, was used to exclude the possibility
that diffusion was due to an increase in cellular edema. CBX
signiﬁcantly blocked LY diffusion in both WT and MK4 ipsilat-
eral cortex compared with non–CBX-treated counterparts
(Fig. 5, A and B). LY diffusion was similar in both CBX-treated
WT and MK4 ipsilateral and contralateral brain slices (Fig. 5, A
and B).
While the in situ scrape-loading assay showed an increase in
connexin-dependent LY diffusion, it is possible that other con-
nexins, such as those expressed in neurons and/or other glial
cell types, may have also contributed to LY diffusion. To in-
vestigate the role of Cx43 GJ in astrocytes speciﬁcally, an in vitro
scrape-loading assay was performed in astrocytes isolated from
WT and MK4 mice. Consistent with the in situ scrape-loading
assay, both hypoxic WT and MK4 astrocytes demonstrated a
signiﬁcant (∼2.5-fold) increase in GJ coupling compared with
their counterpart astrocytes under control conditions (Fig. 5, C
and D). No signiﬁcant differences were observed between gen-
otypes in either normoxic or hypoxic conditions (Fig. 5, C
and D).
Cx43 hemichannel activity is reduced in MK4 astrocytes
To determine whether Cx43 hemichannel activity is affected in
MK4 astrocytes, dye uptake assays as well as single-channel
ischemic buffer plus hypoxia (<1% O2). Right graph shows mean relative band densities for phospho-p44/42 MAPK protein as a function of treatment and
genotype (n = 3). Two-way ANOVA followed by Tukey’s multiple comparisons test, main effect of genotype, P = 0.8297; main effect of treatment, ****, P <
0.0001; interaction P = 0.9022; WT normoxia versus WTmedia: **, P = 0.0038; MK4 normoxia versus MK4 media: **, P = 0.0019. (E) Immunoblot of phospho-
p279/282 Cx43 (upper blot) and γ-tubulin (lower blot) in WT and MK4 astrocytes subjected to media, 3-h ischemic buffer plus normoxia, or 3-h ischemic buffer
plus hypoxia. Right graph shows mean relative band densities for phospho-p279/282 Cx43 protein as a function of treatment and genotype (n = 3). Two-way
ANOVA followed by Tukey’s multiple comparisons test, main effect of genotype: ****, P < 0.0001; main effect of treatment ***, P = 0.0008; interaction, ***,
P = 0.0005; WT normoxia versus WTmedia: ****, P < 0.0001; WT normoxia versusWT hypoxia: **, P < 0.0098; WT normoxia versus MK4 normoxia; ****, P <
0.0001; WT hypoxia versus MK4 hypoxia: *, P < 0.0204. Error bars represent mean ± SEM.
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recordings were performed and compared between WT and
MK4 astrocytes. Decreasing extracellular divalent cations is a
well-known stimulus for hemichannel opening; in line with
this, we found that applying Ca2+- and Mg2+-free solutions
triggered ethidium uptake in WT astrocytes (Fig. 6 A). Inter-
estingly, ethidium uptake was signiﬁcantly less in astrocytes
from MK4 animals, indicating decreased hemichannel function
(WT slope = 42.16 ± 0.3281; MK4 slope = 25.30 ± 0.1738; n = 3).
We next tested ethidium uptake under conditions of 3-h hy-
poxia followed by 1-h reoxygenation, which is known to in-
crease hemichannel activity and decrease GJ coupling in
cortical astrocytes (Orellana et al., 2010). Consistently, we
found that ischemic conditions triggered ethidium uptake in
WT astrocytes (Fig. 6 B), while uptake was signiﬁcantly lower
in MK4 astrocytes (WT slope = 42.98 ± 0.8610; MK4 slope =
31.96 ± 0.5885; n = 6).
Figure 5. Cx43 GJ coupling is similarly up-regulated in the ischemic cortex of WT and MK4 mice. (A) In situ scrape-loading assay showing WT and MK4
ipsilateral and contralateral cortical slices incubated with the GJ-permeable dye LY (green) and the GJ-impermeable dye dextran rhodamine (red), with or
without 100 µM CBX, 2 h after pMCAO. Scale bar = 200 µm. (B) Quantiﬁcation of the total average area in LY pixels normalized to dextran rhodamine pixels in
ipsilateral and contralateral brain slices fromWT andMK4mice 2 h after pMCAO. Two-way ANOVA followed by Tukey’s post hoc test, main effect of genotype/
treatment: ****, P < 0.0001; main effect of brain region (ipsilateral/contralateral), ****, P < 0.0001; interaction, P = 0.1148, WT: n = 5 mice; MK4: n = 5 mice;
WT-CBX treated: n = 3 mice; MK4-CBX treated n = 3. WT ipsilateral versus WT contralateral, **, P = 0.0053; MK4 ipsilateral versus MK4 contralateral, **, P =
0.0078; WT-CBX ipsilateral versus WT ipsilateral **, P = 0.0081; MK4-CBX ipsilateral versus MK4 ipsilateral **, P = 0.0048. (C) In vitro scrape-loading assay
(dotted line shows scrape edge) showingWT and MK4 astrocytes exposed to either media plus normoxia (95% O2/5% CO2) or 3-h ischemic buffer plus hypoxia
(<1%O2) incubated with LY (green) and dextran rhodamine (red). Scale bar = 50 µm. (D)Quantiﬁcation of total average diffusion area in LY pixels normalized to
dextran rhodamine pixels in WT and MK4 astrocytes subjected to either media plus normoxia (95% O2/5% CO2) or 3-h ischemic buffer plus hypoxia (<1% O2).
Two-way ANOVA followed by Tukey’s post hoc test, main effect of genotype, P = 0.2985; main effect of treatment, ****, P < 0.0001; interaction, P = 0.6338,
WT hypoxia versus WT media: **, P = 0.0049; MK4 hypoxia versus MK4 media: **, P = 0.0015; n = 4. Error bars represent mean ± SEM.
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Figure 6. Hemichannel activity is reduced in MK4 astrocytes. (A) Time-lapse measurements of ethidium uptake inWT or MK4 astrocytes exposed to 5 µM
EtBr. At 10 min, solution was changed to Ca2+/Mg2+-free solution (divalent free) to induce hemichannel opening. Linear regression performed in WT and MK4
reveals slopes are signiﬁcantly different (n = 3; ****, P < 0.0001). (B) Time-lapse measurements of ethidium uptake in WT and MK4 astrocytes under normoxic
conditions (green and black lines, respectively) or 3-h hypoxia in ischemic buffer followed by 1-h reoxygenation in media (orange and blue lines, respectively).
After treatment, astrocytes were exposed to 5 µM EtBr for 15 min. Linear regression was performed in WT and MK4 hypoxia/reoxygenation–treated samples;
slopes are signiﬁcantly different (n = 6; **, P < 0.001). (C–E) Patch-clamp studies of hemichannel activity. (C) Current traces in WT astrocytes for voltage steps
indicated on the left. Unitary current activity appeared at both negative and positive Vm when [Ca2+]i was elevated from 50 nM to 200 nM. Gap19 (100 µM,
added via pipette) suppressed unitary activity (red traces). (D) All-point histogram of current activities at negative, positive, and combined Vm. Unitary
conductance of one (O1) or two open hemichannels (O2) are indicated above each peak (mean ± SD). Gap19 abolished all current activity (red peak at baseline).
(E) Charge transfer (Qm) associated with unitary current activities for recordings at −70 and +50 mV (n = 6). *, P < 0.05 versus 50 nM [Ca2+]i; **, P < 0.01; ##,
P < 0.01 versus 200 nM [Ca2+]i. (F) Current traces in MK4 astrocytes. Unitary activity was absent at 200 nM [Ca2+]I, but pretreatment with 35 µM Pep-1 peptide
(1 h) restored activity (blue traces). (G) All-point histogram showing that currents restored by Pep-1 had a single-channel conductance similar to WT. (H) Qm
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We further investigated Cx43 hemichannel properties,
making use of whole-cell patch-clamp experiments in primary
cultured astrocytes. In WT astrocytes, no unitary current ac-
tivities were observed at 50 nM [Ca2+]i (applied through the
pipette), even with voltage steps up to +50 mV. By contrast,
increasing [Ca2+]i to 200 nM provoked unitary currents over a
wide range of positive as well as negative potentials (Fig. 6 C).
All-point histograms for negative and positive membrane po-
tentials (Fig. 6 D) demonstrated a unitary conductance in the
range of 230–245 pS (i.e., close to the approximate value of 220
pS reported for Cx43 hemichannels; Contreras et al., 2003;
Wang et al., 2012). Gap19, a nonapeptide derived from the cy-
toplasmic loop of Cx43 (Fig. 1) and previously shown to inhibit
hemichannel activity without inhibiting GJ coupling (Wang
et al., 2013; Abudara et al., 2014), abolished the unitary cur-
rent activities (Fig. 6 C). Fig. 6 E summarizes membrane charge
transfer data, which was negligible at 50 nM [Ca2+]i while sig-
niﬁcantly enhanced at 200 nM [Ca2+]i and reduced to baseline
by Gap19 added via the recording pipette (Fig. 6 E). As predicted
by the dye-uptake experiments, electrical and chemical (200 nM
[Ca2+]i) stimulation did not trigger any hemichannel current
activity in MK4 astrocytes (Fig. 6 F). We next tested whether
supplying MK4 astrocytes with a cell-penetrating peptide called
Pep-1, composed of Asp-245 to Pro-283 on the Cx43 CT encom-
passing the four Ser residues modiﬁed in MK4 mice (Fig. 1),
could rescue hemichannel activity. Strikingly, preincubating
MK4 astrocytes with Pep-1 rescued hemichannel activities in
MK4 astrocytes at 200 nM [Ca2+]i (Fig. 6 F), which had a unitary
conductance of 220–240 pS (Fig. 6 G; i.e., not different from
those in WT astrocytes) and were associated with signiﬁcantly
increased charge transfer as compared with nontreated as-
trocytes (Fig. 6 H).
To exclude the possibility that the lower unitary hemi-
channel activity is due to a smaller pool of plasma membrane
hemichannels in MK4 astrocytes, we performed Duolink in situ
proximity ligation assays in isolated WT and MK4 astrocytes.
This assay reports the spatial hemichannel organization relative
to GJs through ampliﬁcation of Cx43–ZO-1 complexes that rep-
resent hemichannels (Rhett et al., 2011). As illustrated in Fig. 6 I,
red Duolink ﬂuorescence occurred throughout the cells, while
the yellow signal produced by red-green colocalized spots at GJs
(arrowhead) represents hemichannels in the “perinexus”
(i.e., closely associated with GJs; Palatinus et al., 2012). We
further tested TAT-CT9, a peptide composed of the last nine
amino acids of the Cx43 C-terminal end (Fig. 1) fused to the TAT
(transactivator of transcription) membrane translocation se-
quence; this peptide promotes incorporation of hemichannels
into GJs by competing for ZO-1 binding, for which the four last
amino acids of the C-terminal tail are crucial (Jin et al., 2004).
WT astrocytes treated with 180 µM TAT-CT9 (2 h) displayed
markedly less Duolink ﬂuorescence signal, in line with its pro-
moting effect on hemichannel assembly into GJs (Fig. 6 I).
Quantiﬁcation of the yellow signal relative to the green Cx43
signal corresponding to the normalized plasma membrane
hemichannel fraction showed that the signal in MK4 astrocytes
was not different from the signal in WT cells (Fig. 6 J). Thus, the
lower hemichannel activity in MK4 astrocytes is the conse-
quence of altered gating and not the result of a decreased
hemichannel pool.
Functional deﬁcit is reduced in MK4 mice subjected to pMCAO
To determine whether the signiﬁcant reduction in infarct vol-
ume measured in MK4 mice is correlated with reduced func-
tional deﬁcits, ischemic WT and Cx43 MK4 mice were subjected
to the adhesive tape removal test. In WT mice, pMCAO signiﬁ-
cantly increased the time it took for mice to remove tape from
the left (impaired) paw 3 d after surgery (WT = 39.78 ± 54.90 s
versus MK4 = 7.33 ± 4.30 s; P = 0.0345; Fig. 7 A). In addition, 5
and 9 d after surgery, WT mice exhibited a nonsigniﬁcant la-
tency in tape removal compared withMK4 animals (Fig. 7 A). By
14 and 21 d after pMCAO, WT mice became as efﬁcient on the
tape removal test as their MK4 counterparts (Fig. 7 A). For the
right (nonimpaired) forepaw, there was no signiﬁcant effect of
pMCAO on tape removal latency between the two genotypes
(Fig. 7 B).
At the end of the adhesive tape removal experiment (21 d of
recovery from pMCAO), infarct damage was assessed in both
WT and MK4 mice by thionin staining of brain sections (Fig. 7
C). Fibrotic scar tissue was evident by intense thionin staining
on both WT and MK4 brain sections (Fig. 7 C). This was also
conﬁrmed by intense GFAP+ immunoﬂuorescent staining,
within the glial limitans, indicating formation of glial scar
(Burda and Sofroniew, 2014; Fig. 7 F). Fibrotic scar tissue volume
was increased in thionin-stained brain sections, and a signiﬁcant
(P = 0.0338) 40.0% reduction in scar tissue volume was mea-
sured in brain sections from MK4 mice compared with WT
animals (Fig. 7 D). In thionin-stained sections, cortical loss in the
ipsilateral infarct side with respect to the contralateral side was
evident in bothWT and Cx43MK4mice (Fig. 7 C). Quantiﬁcation
of percent brain loss showed no signiﬁcant difference in cortical
loss in MK4 ipsilateral cortex compared with WT counterparts
(Fig. 7 E). The ipsilateral stroke area showed a signiﬁcant de-
crease in cortical thickness in both WT and MK4 animals com-
pared with contralateral cortex; however, no signiﬁcant
difference between the two genotypes was found (Fig. S3).
WT and MK4 brain sections from mice 21 d after pMCAO
were labeled with GFAP and Cx43 antibodies. In both WT and
MK4 mice, intense GFAP+ and Cx43+ staining was observed in
the infarct tissue (Fig. 7 F). Cx43 expression was increased in
GFAP+ cells, particularly within the glial limitans surrounding
charge transfer data illustrating restoration of opening activities with Pep-1 in MK4 astrocytes (n = 6). **, P < 0.01 compared with 200 nM [Ca2+]i; ***, P <
0.001. (I) Confocal images of Duolink (red) and Cx43 (green) stainings in WT and MK4 astrocytes; yellow colocalization signal corresponds to hemichannels.
WT astrocytes (left) displayed clear hemichannel signal (arrowhead) that was decreased after TAT-CT9 treatment; hemichannel signal was also present in MK4
astrocytes (right). (J) Summary data of normalized yellow signal, demonstrating that the MK4 signal was not different from WT. ***, P < 0.001 WT versus WT
(TAT-CT9). Scale bars = 20 µm. Error bars represent mean ± SEM.
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Figure 7. MK4 mice show improved sensory function and decreased ﬁbrotic scar tissue after pMCAO. (A) Quantiﬁcation of average time to remove
adhesive tape from left (impaired) forepaw. Times −5 and −3 represent days prior to pMCAO. (B) Latencies for right forepawwere unaffected by pMCAO. Two-
way ANOVA with repeated measures followed by Bonferroni’s multiple comparisons test, main effect of genotype, P = 0.1200; main effect of time, P = 0.1178;
subjects (matching), **, P = 0.0027; interaction, P = 0.1534. The observed power for the interactions is 0.588. The effect size of interaction between time and
genotype is 0.3, according to Cohen’s f (medium to large effect). WTmice versus MK4mice 3 d after pMCAO: *, P = 0.0345; WT: n = 7 mice; MK4: n = 8mice. (C)
Thionin-stained sections fromWT and MK4mice 21 d after pMCAO. Arrows indicate ﬁbrotic scar. Scale bar = 2 mm. (D) Quantiﬁcation of scar volume fromWT
and MK4 thionin-stained sections (unpaired Student’s t test; *, P = 0.0338; WT: n = 6 mice; MK4: n = 8 mice). (E) Quantiﬁcation of cortical percent loss with
respect to contralateral cortex between WT and MK4 mice 21 d post-pMCAO (unpaired Student’s t test; P = 0.4221). (F) Example images of GFAP (red) and
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the scar tissue (Fig. 7 F). Quantiﬁcation of GFAP+ cell numbers
and size showed no signiﬁcant difference between the two
genotypes (Fig. 7, G and H). Within the ﬁbrotic scar tissue, large
amounts of cellular debris and/or extracellular matrix protein
were observed that resulted in nonspeciﬁc staining (Fig. 7 F,
zoom).
Blocking Cx43 hemichannel activity is neuroprotective in mice
subjected to pMCAO
We next asked whether the decreased hemichannel activity
exhibited in MK4 astrocytes is a key factor in the neuro-
protective phenotype of these animals subjected to pMCAO. We
subjected WT animals to pMCAO followed by pharmacological
administration of either the hemichannel blocker TAT-Gap19
(Abudara et al., 2014) or its scrambled form, TAT-GAP19-
scrambled. Fusion of Gap19 to the TAT sequence facilitates cel-
lular uptake of the peptide, allowing it to cross the blood–brain
barrier (BBB) after intracarotid injection (Wang et al., 2013;
Abudara et al., 2014). We tested whether i.p. injection of
7.5 µmol/kg Biotin-TAT-Gap19 sufﬁciently crossed the BBB and
was detectable in the brain parenchyma. 10 min after i.p. in-
jection, Biotin-TAT-Gap19 was detected at the level of the basal
lamina around blood vessels, and at 80 min, it was present in
GFAP-positive astrocytes, where it colocalized with Cx43
(Fig. S4).
After 2 h of pMCAO, i.p. injection of either 0.75 μmol/kg or
7.5 μmol/kg TAT-Gap19 signiﬁcantly reduced infarct volume by
47.8% and 77.6%, respectively, 4 d after pMCAO compared with
those mice that received saline or scrambled peptide alone
(Fig. 8, A and B). Mice treated with the negative control TAT-
Gap19-scrambled did not show signiﬁcant changes with respect
to saline controls (Fig. 8, A and B). Mice treated with 7.5 μmol/kg
TAT-Gap19 showed a signiﬁcant reduction in infarct volume
compared with mice treated with 0.75 μmol/kg of TAT-Gap19
(Fig. 8 B).
Discussion
Kinase activity is induced by a plethora of stimuli triggered by
stroke. Cx43 phosphorylation by PKC has been reported to
preferentially occur in the cerebellum (Ma´rquez-Rosado et al.,
2012), an area of the brain that is not affected by our pMCAO
model. In addition, while we show an increase in Cx43 expres-
sion levels in the peri-infarct area 4 d after pMCAO, PKC ex-
pression has been shown to spike during the onset of ischemia
but quickly disappears within the peri-infarct zone at later time
points (Cui et al., 2011; Lucke-Wold et al., 2015). Similarly, in rats
subjected to global ischemia, CK1 activity is down-regulated in
vulnerable hippocampal CA1 neurons (Kaneko et al., 2014).
Therefore, the difference in spatial and/or temporal overlap
between CK1 and PKC with respect to Cx43 expression may
explain the lack of effect on infarct volume as observed here.
Alternatively, a plausible explanation could be that phospho-
rylation of Cx43 by different kinases, triggered by ischemia, may
induce compensatory overlapping responses associated with
PKC and CK1 with regard to Cx43 channels (Pogoda et al., 2016).
These results do not exclude the possibility that PKC or CK1 may
act on Cx43 in other brain pathologies.
In both WT and MK4 ipsilateral cortex, MAPK phosphoryl-
ation was increased compared with the contralateral side 2 h
after pMCAO, in agreement with previous ﬁndings (Wu et al.,
2000). Similarly, MAPK phosphorylation levels were more
pronounced in both WT and MK4 astrocytes when stressed for
3 h in ischemic buffer in vitro, which was directly correlated
with an increase in phosphorylation levels in Ser-279/282 of
Cx43 in WT astrocytes. These ﬁndings are further supported by
a recent study showing that Cx43 phosphorylation is up-
regulated as early as 2 h and as late as 8 h after bilateral com-
mon carotid occlusion in rats and that Cx43 phosphorylation is
blocked by inhibiting MAPK activity (Chen et al., 2017). We
show here that Cx43 phosphorylation at Ser-279/282 was also
detected 24 h after pMCAO (Fig. S5 B).
While several lines of evidence indicate that MAPK-
dependent phosphorylation of Cx43 decreases GJ coupling
(Warn-Cramer et al., 1998; Sirnes et al., 2009; Nimlamool et al.,
2015), the level of GJ coupling in WT astrocytes was similar to
that seen in MK4 astrocytes after 2 h of pMCAO in vivo or 3 h of
exposure to ischemic conditions in vitro. Although our data did
not support a role for MAPK-dependent disruption of GJ cou-
pling in ischemic WT astrocytes, this does not exclude the pos-
sibility that MAPK-dependent reduction of GJ coupling may
have occurred more robustly at a different time point than the
2 and 3 h explored in this study. We detected changes in Cx43
phosphorylation, based on electrophoretic isoforms analyzed by
immunoblot, in the ipsilateral cortex compared with the corre-
sponding contralateral side in both genotypes 2 h after pMCAO.
The faster-migrating P0 isoform detected in both WT and MK4
ipsilateral cortex is not phosphorylated at MAPK sites on Cx43
(Solan and Lampe, 2009). Interestingly, evidence in the litera-
ture indicates that some phosphorylated species migrate with
the P0 band in SDS-PAGE (Solan and Lampe, 2009). Therefore,
one cannot exclude the possibility that the P0 isoform is phos-
phorylated at some other site. It has been shown that the P0
isoform is associated with increased coupling in ischemic as-
trocytes in vivo (Li et al., 1998). Others have reported a link
between GJ coupling and increased astrocyte reactivity in brain
injury (Naus et al., 2001; Siushansian et al., 2001; Ozog et al.,
2002; Nakase et al., 2003; Wallraff et al., 2006; Belousov et al.,
Cx43 (green) labeled brain sections fromWT andMK4mice 21 d after pMCAO. Images on the far right are expanded (2× optical zoom) views of the scar tissue in
the micrographs shown on the left. White arrows indicate scar tissue. Scale bar = 100 µm. The Tile Scan tool and autostitching algorithm in the Leica LAS AF
program was used to create high-resolution image montages. (G) Quantiﬁcation of average number of GFAP+ cells in WT and MK4 mice (unpaired Student’s
t test; P = 0.5215; WT: four sections per mouse, n = 5mice; MK4: four sections per mouse, n = 5mice). (H)Quantiﬁcation of average size of astrocytes inWT and
MK4 mice (unpaired Student’s t test; P = 0.3852; WT: four sections per mouse, n = 5 mice; MK4: four sections per mouse, n = 5 mice). Error bars represent
mean ± SEM.
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2017). Interestingly, a marked increase in GFAP+ astrocyte size
and cell numbers in MK4 mice compared with WT counterparts
was measured. We postulate that Cx43 in both MK4 and WT
mice was subjected to the same ischemia-dependent dephos-
phorylation. However, due to the additional insensitivity of
Cx43 to MAPK phosphorylation in MK4 mice, this may have
contributed to prolonged Cx43 GJ coupling and increased as-
trocyte reactivity within the 4 d of pMCAO. Several lines of
evidence show that reactive astrocytes are involved in neuronal
survival mechanisms in stroke and neurodegeneration (Li et al.,
2008; Kraft et al., 2013; Kamphuis et al., 2015). Therefore, the
increased astrocyte reactivity in MK4 mice, measured 4 d after
stroke, may have contributed to the signiﬁcantly smaller infarct
volumes observed in these animals as well as the reduced ﬁ-
brotic scar at 21 d after stroke.
Previous reports have shown that Cx43 hemichannel activity
under in vitro pathological conditions is linked with inﬂam-
mation and neuronal death (Retamal et al., 2007; Froger et al.,
2010; Orellana et al., 2010, 2011). In agreement with these
reports, the reduced levels of Cx43 hemichannel activity ex-
hibited by MK4 mice is correlated with a reduction in the
number of Iba1+ microglial and TUNEL+ apoptotic cells 4 d after
pMCAO. These ﬁndings, together with other studies, suggest
that reduced hemichannel activity may provide a protective
microenvironment that enables both astrocyte and neuronal
survival after stroke in MK4 animals.
The Duolink assays and immunoblot experiments conﬁrmed
that the differences in hemichannel activity exhibited between
WT and MK4 astrocytes were not due to differences in Cx43
protein levels or hemichannel pool alterations. Furthermore,
electrophysiological evidence demonstrated that Pep-1 peptide
encompassing the WT C-terminal MAPK phosphorylation sites
(Fig. 1) rescued deﬁcient hemichannel activity in MK4 as-
trocytes, indicating that Ser-255, Ser-262, Ser-279, and Ser-282
are crucial for hemichannel function. The hemichannel-
inhibiting peptide Gap19 acts by binding to the C-terminal tail,
thereby preventing intramolecular loop–tail interactions that
are necessary for hemichannels to become available for opening
Figure 8. TAT-Gap19 is neuroprotective in mice subjected to pMCAO. (A) Thionin-stained sections 4 d after pMCAO in WT mice treated with saline,
7.5 μmol/kg i.p. scrambled TAT-GAP19-scrambled, or 0.75 μmol/kg i.p. hemichannel blocker TAT-GAP19 2 h after pMCAO. Black outline highlights the infarct.
Scale bar = 2 mm. (B) Infarct volume 4 d after pMCAO from WT mice treated with saline, TAT-GAP19-scrambled, or TAT-GAP19 2 h after pMCAO (one-way
ANOVA followed by Tukey’s multiple comparisons test; saline versus scrambled: P > 0.9999; saline versus 0.75 μmol/kg TAT-GAP19: **, P = 0.0021; saline
versus 7.5 μmol/kg TAT-GAP19: ****, P = < 0.0001; scrambled versus 0.75 μmol/kg TAT-GAP19: **, P = 0.0019; scrambled versus 7.5 μmol/kg TAT-GAP19:
****, P < 0.0001; 0.75 μmol/kg TAT-GAP19 versus 7.5 μmol/kg TAT-GAP19: *, P = 0.0484; saline: n = 4 mice; 7.5 μmol/kg TAT-GAP19-scrambled: n = 4 mice;
7.5 μmol/kg TAT-GAP19: n = 4 mice; 0.75 μmol/kg TAT-GAP19: n = 4). Error bars represent mean ± SEM.
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(Ponsaerts et al., 2010; Wang et al., 2013; Fig. 9). In line with
deﬁcient loop–tail interaction in MK4 animals, we recently
found that Ser-279 and Ser-282, in addition to the last nine
amino acids of the C-terminal end (Arg-374–Ile-382, marked
purple in Fig. 1), are crucial for hemichannel function
(Iyyathurai et al., 2018). The Ser-279/Ser-282–containing do-
main (called the Src homology 3 or SH3 domain, Pro-274–Pro-
284) and the CT9 domain appear to be involved, with mod-
iﬁcations in one of these domains giving diminished Cx43
hemichannel activity and modiﬁcations in both resulting in
complete hemichannel block. The present data indicate that Ser
to Ala modiﬁcation in the longer His-248–Lys-287 stretch, con-
taining Ser-255, Ser-262, Ser-279, and Ser-282, produces almost
complete loss of hemichannel function, thereby protecting the
brain. The data presented here suggest that phosphorylation on
one or more of the MAPK consensus Ser phosphorylation sites
may play a role in the loop–tail interaction.
Taken together, the data highlight MAPK as a player in is-
chemic damage within the context of Cx43 function. Interest-
ingly, this intracellular kinase has been reported to exhibit both
beneﬁcial and detrimental effects that may be context depen-
dent (i.e., cell type or temporal activation of MAPK; Sawe et al.,
2008). Indeed, several reports have demonstrated that MAPK
inhibition is beneﬁcial in stroke (reviewed in Sun and Nan,
2016). This is consistent with the beneﬁcial effect of inhibiting
or disrupting MAPK phosphorylation of Cx43 in ischemic
conditions.
Several studies with nonspeciﬁc GJ/hemichannel blockers
such as halothane, octanol, and CBX have demonstrated pro-
tective effects on infarct size or cell death in various permanent
or transient animal stroke models (Warner et al., 1995;
Rawanduzy et al., 1997; Saito et al., 1997; Rami et al., 2001; de
Pina-Benabou et al., 2005; Perez Velazquez et al., 2006). Work
with more speciﬁc connexin mimetic peptides like Gap26 or
Gap27, which ﬁrst block hemichannels and, with some delay,
GJs, also reduced infarct size and cell death, and promoted
functional recovery, even if added 24 h after ischemia. The effect
was explained by alterations in the trafﬁcking and degradation
of Cx43 and reduced extracellular glutamate but hemichannel
function was not tested (Li et al., 2015). Peptide 5, which blocks
hemichannels at low concentrations and inhibits GJs at higher
concentrations, was reported to prevent seizure activity and
brain weight loss in fetal sheep following transient bilateral
clamping of the carotid arteries (peptide administered directly
in brain ventricles; Davidson et al., 2012). While evidence in the
literature broadly implicates Cx43 in ischemia, the data pre-
sented in this study underscore Cx43 hemichannels as a key
focal point in stroke.
We tested this hypothesis by using Gap19, a peptide which
has been shown to inhibit astroglial Cx43 hemichannels while
not affecting GJ coupling (Abudara et al., 2014). Gap19 is speciﬁc
to Cx43 and was demonstrated to cross the BBB when coupled to
the TAT protein (Abudara et al., 2014). The administration of
TAT-Gap19 2 h after pMCAO inWTmice resulted in a signiﬁcant
reduction in infarct volume 4 d after stroke, conﬁrming the
hypothesis that Cx43 hemichannels are a major contributing
factor to injury in stroke. While Cx43 loop–tail interactions are
necessary for hemichannel function, they result in closure of GJs
(Leybaert et al., 2017). Thus, preventing loop–tail interaction
with L2 or L2-derived peptides was shown to protect against
ischemic acidosis-induced GJ closure in cell expression systems
(Morley et al., 1996; Verma et al., 2009, 2010), and the Cys-
260–Asn-300 region containing three of the four MAPK con-
sensus Ser phosphorylation sites has been proposed, next to
others, to be involved in this protection (Morley et al., 1997).
However, because GJs were not affected in the MK4 animals, GJ-
linked protection does not appear to be involved in the presently
used pMCAO model.
While measuring Cx43 expression at different time points
would yield a more complete picture, our goal in this study
was to investigate a therapeutic window of time where Cx43
activity could be understood and pharmacologically manipu-
lated. We examined two features of Cx43 function that may
be potential targets for neuroprotection, speciﬁcally, the po-
tential protective beneﬁts provided by GJ coupling and the det-
rimental hemichannel activity, which may be linked to MAPK
Figure 9. Model for MAPK consensus Ser phosphorylation sites in loop–tail interaction and regulation of Cx43 hemichannel function. Interaction of
CL with MAPK consensus phosphorylation site encompassing Ser-255, Ser-262, Ser-279, and Ser-282 on the CT (blue interaction cloud) brings hemichannels
into a state available for opening. Modiﬁcation of the four Ser residues to Ala in MK4 animals prevents loop–tail interaction and therefore prevents hemi-
channel opening. Gap19 prevents hemichannel opening by binding to the CT, thereby hindering loop–tail interaction. NT, N-terminal end; EL, extracellular loop;
CL, cytoplasmic loop.
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phosphorylation. This study provides signiﬁcant new insight on
the potential therapeutic strategies that revolve around as-
trocytic Cx43 in brain injury.
Materials and methods
pMCAO
C57BL/6 WT and Cx43-null phosphorylation knock-in mutant
mice MK4 Cx43 (Ser-255/262/279/282A; Johnstone et al., 2012),
CK1 Cx43 (Ser-325A/328Y/330A), and PKC Cx43 (Ser-368A;
Huang et al., 2011) weremaintained on a 12:12-h light/dark cycle,
with food and water available ad libitum. Male and female WT
and mutant mice were subjected to pMCAO, as previously de-
scribed (Nakase et al., 2004). Brieﬂy, 3–4-mo-old mice were
anesthetized with 65 mg/kg sodium pentobarbital (i.p.) and
given an opiate (0.1 mg/kg buprenorphine) and a local analgesic
(0.1 ml bupivacaine at 0.25%) at incision before surgery. Body
temperature was maintained at 37°C during surgery and re-
covery. The head was held securely in place using a stereotaxic
frame (David Kopf Instruments). With the aid of a dissecting
microscope (Hund Wetzlar), a skin incision was made on the
right side of the head from the anterior of the ear toward the
corner of the eye horizontally and from the corner of the eye
vertically 5 mm. Using a ﬁne battery-powered drill (Dremel), a
small hole was made ∼2 mm in diameter on the skull bone to
remove dura and expose the MCA. The MCA was then cauter-
ized above and below the rhinal ﬁssure using an electronic co-
agulator (Codman & Shurtleff). After visually conﬁrming the
absence of reperfusion through the MCA, the skin incision was
closed and mice were given a 1-ml subcutaneous bolus of lactate
Ringer’s solution. After surgery, the mice were monitored for
body temperature and maintained at 37°C with a rectal probe
until they started to wake up from the anesthetic ∼2 h later, at
which time the animals were then placed in their home cages on
a heating pad set at 37°C for 12 h.Micewere then transferred to a
temperature-controlled (22.0°C) recovery room for the re-
maining 4 d and monitored daily.
In a separate cohort, WT mice were subjected to the same
pMCAO protocol as above; however, after 2 h of ischemia, mice
were then given an i.p. injection of saline, 0.75 μmol/kg or
7.5 μmol/kg of the hemichannel blocker TAT-Gap19 (Wang et al.,
2013; Abudara et al., 2014), or 7.5 μmol/kg of the inactive
scrambled TAT-GAP19. Mice were then euthanized 4 d after
pMCAO and brains subjected to histological assessment of in-
farct volume.
The pMCAO experiments performed in this study conform to
the following STAIR requirements. (1) Randomized and blinded
studies: our animals were randomly selected and coded for
blinded study. (2) Efﬁcacy in two or more laboratories: the ﬁrst
group of pMCAO surgeries was performed at the Fred Hutch-
inson Cancer Research Center, and the second set of pMCAO
surgeries was performed at the University of British Columbia.
(3) Consideration of sex difference: male (WT = 4; MK4 = 4) and
female (WT = 6; MK4 = 7) infarct volume data were subjected to
two-way ANOVA. Two-way analysis indicated a signiﬁcant
main effect of MK4 genotype (F (1, 17) = 11.52; **, P = 0.0035), and
main effect of sex (F (1, 17) = 5.204; *, P = 0.0357); however, no
signiﬁcant interaction between sex and genotype (F (1, 17) =
0.4036; P = 0.5337) was observed. (4) Consideration of route of
administration: we previously published a study that examined
vascular delivery of TAT-Gap19 (Abudara et al., 2014), clearly
demonstrating this as an effective route of administration.
However, in the current study, we clearly show that Biotin-
TAT-Gap19 readily enters the brain following i.p. delivery
(Fig. 8). (5) Consideration of a clinically useful therapeutic
window and dose response: the therapeutic window considered
in our experiments was the administration of TAT-Gap19 2 h
after pMCAO. This is within the clinical time frame for the
optimal administration of tissue plasminogen activator (Cheng
and Kim, 2015). While a formal and complete dose response was
not performed in our study, Fig. 8 shows a signiﬁcant reduction
in infarct volume when a 10-fold dilution of TAT-Gap19 is ad-
ministered 2 h after pMCAO. Finally, if there were hemor-
rhaging due to poor cauterization, animals were excluded from
study. Inclusion was based on visual inspection and conﬁrma-
tion of the MCA occlusion. No mortality occurred during these
experiments.
In vivo administration of Biotin-TAT-Gap19
Healthy male C57/B6mice (84–112 d) received an i.p. injection of
7.5 µmol/kg Biotin-TAT-Gap19 (Pepnome) and were sacriﬁced
10 or 80 min later through transcardial perfusion with PBS.
Following their isolation, brains were immediately snap-frozen
in liquid N2-cooled isopentane and stored at −80°C. 20-µm
coronal cryosections were postﬁxed in 4% paraformaldehyde
on glass coverslips for 25 min and permeabilized/blocked in PBS
containing 0.2% Triton X-100 and 0.4% porcine skin gelatin for
1 h at room temperature. The sections were then treated with
the following primary antibodies: mouse anti-GFAP (1:
100 GFAP-Cy3; Sigma-Aldrich), rat anti-CD31 (1:50; Life Tech-
nologies Invitrogen), rabbit anti-laminin 1+2 (1:100; Abcam), or
rabbit anti-Cx43 (1:100; Sigma-Aldrich). Secondary antibodies
(goat anti-rat DyLight 650 and goat anti-rabbit Alexa Fluor 594;
Life Technologies Invitrogen) were used at 1:500 dilutions in
permeabilization/blocking buffer. Biotinylated TAT-Gap19 was
detected using Streptavidin–Alexa Fluor 488 (1:200 in PBS). As a
control for endogenous biotin, we also applied Streptavidin–
Alexa Fluor 488 to cryosections of animals injected with vehicle
only and found no staining. Sections were mounted in Prolong
Gold anti-fade reagent containing DAPI. Omission of primary
antibodies served as negative controls. Confocal images were
acquired on a TCS SP8 laser-scanning confocal microscope
equipped with a 63×/1.2 numerical aperture water objective
(Leica Microsystem). Colocalization of Biotin-TAT-Gap19 with
GFAP, CD31, Laminin, or Cx43 was analyzed using the colocali-
zation plug-in for ImageJ (available at http://rsbweb.nih.gov/ij/).
Quantiﬁcation of cerebral infarction
Infarct volume was quantiﬁed as previously described (Kozoriz
et al., 2010). 4 d or 21 d after pMCAO, WT and phosphorylation-
null mutant mice were anesthetized using a lethal dose of so-
dium pentobarbital (120 mg/kg i.p.) and transcardially perfused
with PBS, followed by 10% formalin (Sigma-Aldrich). A cryostat
(HM 505E; Micron) was used to obtain 20-µm- and 10-µm-thick
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sections collected at 100-µm intervals for infarct volume de-
termination and immunocytochemistry. To measure infarct
size, sections were stained with 0.125% thionin (Fisher Scien-
tiﬁc). Total infarct volumes were calculated using a stereological
approach through the rostrocaudal extent of the infarct area and
corrected for edema as previously described (Lin et al., 1993).
Images were analyzed with ImageJ software.
Immunoﬂuorescence and quantiﬁcation
We have extensively studied the time course of injury following
pMCAO, and 4 d provides an optimal time point to assess not
only infarct volume but also neuronal injury and glial reactivity
(Nakase et al., 2004). Immunoﬂuorescence was performed as
previously described (Freitas-Andrade et al., 2012). Incubation
of primary antibodies were performed overnight at 4°C in PBS +
10% goat serum. Primary antibodies and their dilutions used
were as follows: rabbit anti-Iba1 (1:400; catalog number
019–19741; Wako) to identify microglial; rabbit anti-GFAP (1:
1,000; catalog number G3893; Sigma-Aldrich) to identify as-
trocytes; Cx43-phospho-Ser-279/Ser-282 (1:1,000, generously
provided by P.D. Lampe); and rabbit anti-Cx43 (1:600; catalog
number C6219; Sigma-Aldrich). Both Cx43-phospho-Ser-279/
Ser-282 and rabbit anti-Cx43were tested for speciﬁcity (Fig. S5).
Appropriate secondary Alexa Fluor antibodies (Invitrogen) were
used at 1:500 dilutions in PBS buffer. Sections were mounted
with Prolong Gold anti-fade reagent with DAPI (Invitrogen).
Omission of primary antibodies served as negative controls.
Apoptosis was measured with In Situ Cell Death Detection Kit,
Fluorescein (Sigma-Aldrich).
Histological quantiﬁcation was performed as previously de-
scribed (Freitas-Andrade et al., 2012). At least four mice per
genotype (WT and MK4) were analyzed. Four serial brain sec-
tions (100-µm intervals) from each animal at the level of the
frontal cortex were used for immunoﬂuorescent analysis. Im-
ages containing the peri-ischemic area, speciﬁcally in the dorsal
cortex, were captured by confocal microscopy Leica TCS SP5 II
(Leica Nussloch) objectives used: 20×/0.50 PH2-HCX PI Fluortar
inﬁnity/0.17/E, and 63×/1.4-0.6 Oil Cs HCX- PL-APO. The Leica
LAS AF program was used to acquire images at room tempera-
ture (22°C). For quantiﬁcation of cell numbers, a selected ﬁeld
(960 × 600 µm) encompassing the peri-infarct region of the
dorsal cortex was analyzed using ImageJ software. The average
of four brain sections per mouse (four mice per genotype) was
analyzed and plotted.
Western blot analysis
Protein samples from WT and MK4 cortical tissue as well as
cultured astrocytes from both genotypes were resolved by SDS-
PAGE as described previously (Freitas-Andrade et al., 2012).
Brieﬂy, 40 µg protein was separated on a 12% SDS–
polyacrylamide gel and transferred to polyvinylidene diﬂuoride
membranes. Membranes were processed and incubated over-
night at 4°C with primary antibodies against Cx43 (1:5,000;
catalog number C6219; Sigma-Aldrich), Cx43-phospho-Ser-279/
Ser-282 (1:1,000, generously provided by P.D. Lampe), MAPK (1:
1,000; catalog number 9101; Cell Signaling Technology), and
mouse anti-γ-tubulin (1:3,000, catalog number T6557; Sigma-
Aldrich) in Tris-buffered saline (Tris 50 mM and NaCl 150 mM,
pH 8.0) containing 0.05% Tween (TBST) in 1% nonfat dry milk.
The membranes were washed and incubated with horseradish
peroxidase–conjugated secondary antibody (Vector Laborato-
ries) 1:5,000 in TBST containing 5% nonfat dry milk. Immuno-
reactive proteins were visualized by chemiluminescent solution
(Super Signal West Pico; Pierce Biotechnology). Densitometric,
semiquantitative analysis of Western blots was performed using
ImageJ software. Band intensity measurements obtained from
proteins of interest were normalized to housekeeping protein
(γ-tubulin) values. In addition, individual Western blots were
loaded with a standard sample obtained from a mixture of E18
and 9-mo-old ischemic brain homogenates to permit compar-
isons made between blots.
Astrocyte isolation and in vitro hypoxia
WT and MK4 astrocytes were isolated from early postnatal
(P0–P1) cortices as previously described (Le et al., 2014). Dis-
sected cortices were triturated in DMEM (Sigma-Aldrich). The
suspension was passed through a 70-µm cell ﬁlter and then
seeded into ﬂasks (two cortices per T75 ﬂask). Culture media
(DMEM supplemented with 10% FBS, 10 U/ml penicillin, and
10 µg/ml streptomycin) was replaced 3 d after plating and every
second day thereafter. Before each feeding, cell culture ﬂasks
were shaken for 1 min and rinsed twice with media; this reduces
microglial contamination to ∼2%. After 7–8 d in vitro, astrocytes
were then harvested with trypsin-EDTA (Invitrogen) and frozen
in freezing medium (90% FBS and 10% DMSO). Frozen as-
trocytes were thawed and plated on glass coverslips coated with
0.01% solution poly-L-ornithine (Sigma-Aldrich) or culture
dishes. Cultures were maintained for 5–7 d before experiments.
All experiments were performed on conﬂuent astrocytes and
performed independently at least three times. Astrocytes iso-
lated from different breeding pairs were used for each set of
experiments (Le et al., 2014).
WT and MK4 astrocytes were exposed to 3 h of hypoxia as
previously described (Orellana et al., 2010) in an artiﬁcial cer-
ebrospinal ﬂuid medium that mimics the interstitial ionic con-
centrations of ischemic brain “ischemic buffer” (Bondarenko
and Chesler, 2001; Orellana et al., 2010; in mM: 51 NaCl,
65 K-gluconate, 0.13 CaCl2, 1.5 MgCl2, and 10 Hepes, pH 6.8)
containing 27 mM glucose. Hypoxia was induced by placing the
cultures inside a hypoxic chamber and removing the air with a
CO2/N2 (5%/95%) ﬂow that maintained <1.0% oxygen through-
out the duration of the experiment. Astrocytes were removed
and processed immediately for immunocytochemistry and
Western blot analysis.
In situ scrape-loading dye-transfer assay
The scrape-loading assay allows the introduction of a GJ-
permeant ﬂuorescent dye, such as LY into cells and to monitor
its propagation into GJ-coupled cells within minutes after load-
ing (Desarme´nien et al., 2013). The scrape-loading experiment
performed in this study is a modiﬁcation of a previously de-
scribed method (Desarme´nien et al., 2013). Brieﬂy, WT and MK4
mice were subjected to 2 h of pMCAO. After the 2 h, the mice
were euthanized with an overdose of sodium pentobarbital
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(120 mg/kg i.p.). The brains were quickly removed and sliced
into 350-µm-thick coronal slices with a manual tissue chopper.
The coronal slices used for this assay encompass the region of
the brain normally affected by our stroke model. The ipsilateral
area of the cortex affected by the stroke (parietal-temporal
cortex) was then scraped with a 26-gauge needle containing a
small mixture (10 µl) of the GJ-permeant ﬂuorescent dye LY
(444-Dmolecular weight [MW]) and GJ-impermeant ﬂuorescent
dye dextran rhodamine (10,000-D MW). The same cortical area
(parietal-temporal cortex) of the contralateral cortex was simi-
larly treated. After a 50-s incubation, brain slices were imme-
diately ﬁxed in paraformaldehyde (4% in 0.1 M phosphate
buffer) and stored at 4°C. Brain slices were then cryosectioned at
10 µm thickness and imaged with an epiﬂuorescence Zeiss Ax-
ioplan2 ﬂuorescence microscope (Carl Zeiss). Dye spreading was
quantiﬁed by measuring the area (in pixels) of LY diffusion
subtracted by the area of the GJ-impermeable reference dye,
dextran rhodamine, with ImageJ software. In addition, a cohort
of control coronal slices was incubated for 5 min with a Cx43
channel blocker, 100 µM CBX, before the scrape-loading assay.
In vitro scrape-loading dye-transfer assay
After hypoxia treatment, dye entry was induced by scraping a
conﬂuent monolayer of WT and MK4 astrocytes, incubated with
50 µl of the GJ-permeable dye LY (0.5%) and GJ-impermeable
dye dextran-rhodamine (0.05%; 10 kD) in PBS, with a scalpel
blade and allowing the dyes to incubate for 2 min. Excess dye
was washed off with several rinses of PBS. The extent of cou-
pling was determined by epiﬂuorescence Zeiss Axioplan2 ﬂuo-
rescence microscope at 22°C (objective 16×/0.50 Imm-Plan-
NeoFluar, Inﬁnity/0.17) measuring the area (in pixels) of LY
diffusion subtracted by the area of the GJ-impermeable refer-
ence dye, dextran rhodamine, with ImageJ software (Kozoriz
et al., 2013).
Hemichannel assay
Time-lapse ﬂuorescence imaging to measure hemichannel ac-
tivity was performed as previously described (Kozoriz et al.,
2013). WT and MK4 astrocytes in cell culture dishes were
washed twice with Locke’s solution containing (in mM) 154
NaCl, 5.4 KCl, 2.3 CaCl2, and 5 Hepes, pH 7.4, and incubated in
5 mM ethidium bromide (EtBr). Fluorescence intensity was re-
corded every 30 s for 10 min to establish background ﬂuores-
cence with a Zeiss Axioplan2 ﬂuorescence microscope (objective
16×/0.50 Imm-Plan-NeoFluar, Inﬁnity/0.17) at 22°C. To induce
hemichannel activity, cells were then switched to Ca2+/Mg2+-
free solution, and ﬂuorescence intensity was measured every
30 s for 20 min. Images of ethidium uptake were analyzed with
ImageJ software. Each point corresponds to the mean ± SEM of
>100 cells in triplicate experiments. Linear regression was
performed on a dataset from the Ca2+/Mg2+-free solution por-
tion of the line, and slopes were statistically compared.
Hemichannel activity was also similarly measured inWT and
MK4 astrocytes subjected to either control media conditions or
3-h hypoxia followed by 1-h reoxygenation in ischemic buffer
conditions according to a previously published report (Orellana
et al., 2010).
Electrophysiological recordings of Cx43 hemichannels
Isolated WT and MK4 astrocytes were cultured in DMEM con-
taining 10% heat-inactivated newborn calf serum and 100 U/ml
penicillin-streptomycin. When astrocytes became conﬂuent on
days 10–15, they were suspended by trypsin-EGTA and replated
on glass coverslips for at least 3 h before whole-cell patch-clamp
recordings. The procedure yields round shaped and single as-
trocytes in culture, making stable electrophysiological record-
ings possible. The treatment did not affect either membrane
fraction of connexins or hemichannel activities. The extracel-
lular solution for whole-cell recording consisted of (in mM) 130
NaCl, 10 CsCl, 1 MgCl2, 1.8 Ca2+, 10 Hepes, and 5 glucose (pH 7.4),
while the standard whole-cell recording pipette solution was
composed of (in mM) 130 CsCl, 10 Na-aspartate, 0.26 CaCl2,
1 MgCl2, 2 EGTA, 7 tetraethylammonium-Cl, and 5 Hepes; pH
was adjusted to 7.2. Free Ca2+ concentration was 50 nM as cal-
culated with the Webmax Standard software application
(Patton, 2003), while the estimations of attained [Ca2+]i men-
tioned in the results were also calculated using this software.
Whole-cell currents were recorded by an EPC 7 PLUS patch-
clamp ampliﬁer (HEKA Electronik). Data were digitized at 3.3
KHz using a NI USB-6221 data acquisition device (National In-
struments), and WinWCP acquisition software designed by Dr.
J. Dempster (University of Strathclyde, Strathclyde, UK). Mea-
sured currents were ﬁltered by a 7-pole Bessel low-pass ﬁlter at
1-KHz cutoff frequency. Voltage stimulation consisted of 10-mV
incremental voltage steps from −70 to +50 mV with astrocytes
initially held at −70 mV.
For single-channel analysis, unitary current events were
obtained by subtracting holding currents from the recorded
traces. Unitary conductances were calculated from the elemen-
tary current transitions Δi as γ = Δi/Vm followed by construc-
tion of all-point conductance histograms that display one or
more Gaussian distributions. Channel activity was quantiﬁed
from the charge transfer Qm through open hemichannels. This
is equal to integral of the unitary current traces (i.e., a function
of time) over the duration of the voltage steps.
Duolink assay: Immunohistochemistry, image acquisition,
and analysis
Astrocytes were ﬁxed in 2% paraformaldehyde for 10 min and
permeabilized by 0.2% Triton X-100. Following 1-h incubation
with blocking media composed of 5% bovine serum albumin and
10% goat serum, ﬁxed cells were treated with primary anti-
bodies against Cx43 (C-terminal region; produced in rabbit;
Sigma-Aldrich) and ZO-1 produced in mouse (Invitrogen,
Thermo Fisher Scientiﬁc). To detect the subpopulation of
Cx43–ZO-1 complexes, Duolink secondary antibodies, PLA probe
anti-rabbit MINUS, and anti-mouse PLUS (Sigma-Aldrich) tar-
geting the primary antibodies were applied at 37°C for 1 h. The
oligonucleotides conjugated to the probes form a closed circle
under the treatment of Duolink ligation assay when the maxi-
mum distance between the two target proteins was 40 nm. The
resulting closed circles were ampliﬁed by polymerase and
further recognized by ﬂuorescently labeled oligonucleotides
(Duolink In Situ Detection Reagents Red; Sigma-Aldrich)
with complementary sequences. A third primary anti-Cx43
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(N-terminal) antibody was used to stain the total Cx43 proteins
in astrocytes (ABGENT; VWR International). The speciﬁcity of
the Duolink assay was veriﬁed by incubating astrocytes with a
CT9 peptide (RPRPDDLEI) conjugated to a membrane-
penetrating sequence TAT (180 µM, 2 h) before the ﬁxation.
The CT9 peptide, which mimics the C-terminal sequence of
Cx43, was previously shown to inhibit the interaction between
the Cx43 CT tail and the PDZ2 domain of ZO-1, thereby pro-
moting incorporation of hemichannels into GJ plaques (Palatinus
et al., 2012). Cell nuclei were stained with DAPI (1 µg/ml), and
the preparations were then mounted in proLong Gold antifade
reagent (Thermo Fisher Scientiﬁc). Confocal images were ac-
quired on a TCS SP8 laser-scanning confocal microscope
equipped with a 63×/1.2 numerical aperture water objective
(Leica Microsystems). We deﬁned GJ plaques as green spots with
a surface area larger than 0.7 µm2. The number of colocalized
spots between the green GJ signal and red Duolink puncta was
quantiﬁed using the puncta analyzer plug-in (developed by Bary
Wark, available on https://github.com/physion/puncta-
analyzer) for NIH ImageJ 2.0 and expressed as the percentage
of total GJ plaques that were colocalized with Cx43/ZO1 com-
plexes. This score represents the hemichannel pool linked to
ZO-1 scaffolding protein underway for assembly into GJs
(Rhett et al., 2011; Rhett and Gourdie, 2012).
Behavioral assessment of forepaw sensory-motor function
The adhesive tape removal test is considered a sensitive and
objective method for detecting deﬁcits in forepaw sensation that
are commonly found after stroke in the sensorimotor cortex
(Bouet et al., 2009; Sweetnam et al., 2012). The behavioral ad-
hesive removal test to assess sensory and motor function of the
forepaw was performed as previously described (Bouet et al.,
2009; Sweetnam et al., 2012). The adhesive removal test was
administered at weekly intervals for 2 wk before pMCAO and 3
wk after pMCAO in both WT and MK4 animals. Brieﬂy, a rect-
angular piece of tape (4 × 3 mm) was placed on the palm of each
forepaw.Mice were then placed in a Plexiglas box and ﬁlmed for
120 s, and two observers blind to the condition scored the time
taken to remove tape from each paw.
At the end of the experiment, mice were euthanized and the
brain assessed histologically for scar tissue volume following the
same protocol used to measure infarct volume. Percent loss was
evaluated by measuring the average cortical area of ipsilateral
and contralateral brain sections, and then the percentage of
cortical tissue loss of the ipsilateral with respect to the contra-
lateral for each animal was calculated. We also performed cor-
tical thickness measurements following a protocol recently
published (Vetreno et al., 2017). Brieﬂy, vertical cortical thick-
ness through the posterior cingulate cortex was calculated by
measuring the distance (in millimeters) from the crest of the
genu of the corpus callosum to the outer layer of the dorsal ce-
rebral cortex. Horizontal cortical thickness through the parietal/
occipital cortex was calculated by measuring the distance (in
millimeters) from the crest of the genu of the corpus callosum to
the edge of the lateral cerebral cortex affected by the stroke.
Quantiﬁcation was performed on sections that clearly showed
the crest of the genu of the corpus callosum as a reference point
for measurements and consistency between samples (bregma
0.74 mm to bregma −1.82 mm). Captured images were assessed
using ImageJ software.
Pharmacological tools
CBX disodium was purchased from Tocris Bioscience. Gap19
(KQIEIKKFK; MW 1,161 D), TAT-Gap19 (YGRKKRRQRRR-
KQIEIKKFK; MW 2,930 D) and scrambled TAT-Gap19
(YGRKKRRQRRR-IEKFKIKQK) were synthesized by Pepnome
(>95% purity). Pep-1 was composed of a TAT-linked sequence
coupled to a peptide composed of the Cx43 sequence Asp-245-
Pro-283 (YGRKKRRQRRR-DPYHATSGALSPAKDCGSQKYAYF-
NGCSSPTAPLSPMSP; Gangoso et al., 2014) and was a kind gift
from Dr. A. Tabernero (University of Salamanca, Salamanca,
Spain).
Statistics
Animals for surgery and cell isolation were randomly selected,
and an experimenter blinded to the genotype performed meas-
urements. Single two-way ANOVA (between two factors) was
used to explore most variables of interest, unless the same an-
imal was repeatedly tested over time then a two-way repeated
measures ANOVA was used followed by Bonferroni’s multiple
comparisons test. A one-way ANOVA (one factor) was used to
compare multiple means to a single control followed by Bon-
ferroni post hoc test, unless multiple means were compared
against each other than Tukey post hoc test was recommended.
Unpaired t tests were performed when comparing two groups.
All P values ≤0.05 were considered statistically signiﬁcant.
Statistical analysis was performed using Prism 6 (Graph Pad).
All data are presented as the mean ± SEM.
Study approval
The ﬁrst group of pMCAO surgeries was performed at the Fred
Hutchinson Cancer Research Center (FHCRC), and all animal
procedures were approved by the FHCRC Institutional Animal
Care and Use Committee. All other pMCAO surgeries were
performed at the University of British Columbia and approved
by the UBC Animal Care Committee and performed in accor-
dance with the guidelines established by the Canadian Council
on Animal Care.
Online supplemental material
Fig. S1 describes in more detail the immunoﬂuorescence quan-
tiﬁcation used to measure astrocytes and microglial cell number
and size. Fig. S2 shows the unique astrocytic phenotype ex-
hibited by MK4 mice 4 d after pMCAO. Fig. S3 demonstrates
another method used to measure cortical thickness in WT and
MK4 mice 21 d after pMCAO. Fig. S4 shows Biotin-TAT-Gap19
BBB penetration. Fig. S5 demonstrates speciﬁcity of phospho-
p279/282 Cx43 and rabbit anti-Cx43 antibodies.
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